Bio-Gene Technology Limited
Bio-Gene Technology Limited
Your view on BGT.AX
Overview
What the company does, where it operates, and who runs it.
About Bio-Gene Technology Limited
- Industry
- Agricultural Inputs
- Sector
- Basic Materials
- CEO
- Timothy Owen Grogan
- Headquarters
- 456 Lonsdale Street, Melbourne, VIC, AU
- Industry
- Agricultural Inputs
- Sector
- Basic Materials
- CEO
- Timothy Owen Grogan
- Headquarters
- 456 Lonsdale Street, Melbourne, VIC, AU
Bio-Gene Technology Limited, an agricultural technology firm based in Australia, focuses on the development and commercialization of insecticides and pesticides. These solutions are designed for a range of uses, encompassing animal health, crop protection, public health, and consumer applications. The company's key products include Flavocide, an insecticide utilizing beta-triketone technology, and Qcide, a natural oil derived from a specific cultivar of eucalyptus cloeziana. Bio-Gene maintains a research partnership with James Cook University to develop a tissue culture system, a critical step for expanding tree plantations and increasing future Qcide oil production. Furthermore, the company collaborates with BASF, the Grains Research and Development Corporation, and the Queensland Department of Agriculture and Fisheries to assess its products' effectiveness against grain storage pests. Established in 1995, Bio-Gene Technology Limited operates from its headquarters in Melbourne, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Bio-Gene Technology Limited, and the rating behind it. BGT.AX last traded at AUD 0.02; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Bio-Gene Technology Limited. Starting points for Bio-Gene Technology Limited: EPS -AUD 0.0071, beta 0.76 — an Agricultural Inputs name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Bio-Gene Technology Limited. Bio-Gene Technology Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Bio-Gene Technology Limited. Trailing twelve-month EPS for Bio-Gene Technology Limited stands at -AUD 0.0071. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Bio-Gene Technology Limited. Bio-Gene Technology Limited has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Bio-Gene Technology Limited valued side by side against its closest peers. Bio-Gene Technology Limited is measured against Agricultural Inputs peers within the Basic Materials sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Bio-Gene Technology Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Bio-Gene Technology Limited executives and directors. Shares of Bio-Gene Technology Limited have traded between AUD 0.02 and AUD 0.06 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Bio-Gene Technology Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Bio-Gene Technology Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Bio-Gene Technology Limited. Coverage tracks Bio-Gene Technology Limited within Agricultural Inputs (Basic Materials). Press releases and market coverage, newest first.